Dietary supplement for promoting blood circulation and bones and muscles

Abstract

A Bone-Strengthening Pill (BSP) as a dietary supplement to improve blood circulation and strengthen bone and muscle is characterized in that it is made from the following raw materials: Angelica Sinensis, Pseudo-ginseng and Carthamus Tinctorius L. BSP has the following beneficial effects: promoting blood circulation, dredging microcirculatory disturbance, significantly improving the level of human health, improving blood running in bone tissue and muscle tissue, and preventing or repairing microscopic damage of bone, cartilage tissue and muscle tissue.

Claims

1. A method for improving blood circulation and strengthening bone and muscle by administrating a Bone-Strengthening Pill (BSP) to a subject in need thereof, wherein the BSP comprises therapeutically effective amounts of decoctions of (i) Angelica sinensis, Panax notoginseng and Carthamus tinctorius L. or (ii) Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Paeonia lactiflora Pall, Ligusticum wallichii, Polyqala tenuifolia and Panax quinquefolius.

2. The method according to claim 1, wherein the ratio of the decoctions of (i) is Angelico sinensis:Panax notoginseng:Carthamus linclorius L. is 280-320: 55-65:12-18 by weight; and wherein the ratio of the decoctions of (ii) is Angelica sinensis:Panax notoginseng:Carthamus tinctorius L.: Paeonia lactiflora Pall:: Ligusticum wallichii:Polvgala tenuifolia:Panax quinquefolius is 280-320: 55-65 12-18: 80-100:25-35: 25-35 2-5 by weight.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1A is an experimental image of Embodiment 1: the arrow (1) indicated smooth surface and chondrocytes arranging in a columnar manner in the femoral head of the normal rats;

(2) FIG 1B is an experimental image of Embodiment 1: the arrows (2) indicate the femoral head of the model rats has surface necrosis and detachment, collapse and coloboma, and loses chondrocytes;

(3) FIG. 1C is an experimental image of Embodiment 1 which shows the femoral head has smooth surfaceI is free of colobomaI and recovered chondrocles in columnar arrangement in the femoral head necrosis when the rats were treated with this product (treatment group);

(4) FIG. 1D is an experimental image of Embodiment 1: the arrows (1-1) indicate crimpinessI disorder and fracture of bone trabecula in the model rats;

(5) FIG. 1E is an experimental image of Embodiment 1: the arrows (1-2) indicate the focal necrosis of intramedullam cells of femoral head;

(6) FIG. 1F is an experimental image of Embodiment 1: the arrows 13) indicate rich and morphology in the bone trabecula in the treatment group;

(7) FIG. 1G is an ex erimental ima e of Embodiment 1: the arrows (4) indicate no necrosis in myeloid cells in the treatment group;

(8) FIG. 1H is an experimental image of Embodiment 1: the arrows (5) indicate a small number of fat particles that were attached to the chondrocyte surface of the normal rat;

(9) FIG. 1I is an experimental image of Embodiment 1: the arrows (6) indicate a large number of fat particles that were contained in the chondrocytes of femoral head of the model rats;

(10) FIG. 1J is an experimental image of Embodiment 1: the arrows (7) indicate a small number of fat particles in the femoral head of the rats in the experimental group;

(11) FIG. 1K is an experimental image of Embodiment 1 which shows the capillaries of femoral head of the normal rats are abundantI with clear edges and interweaving into a network to form an arcuate cup;

(12) FIG. 1L is an experimental image of Embodiment 1 which shows the capillaries inside the femoral head ofthe model rats were sparse and the arcuate cup disappeared;

(13) FIG. 1M is an exgerimental image of Embodiment 1 which shows the cagillaries of the femoral head of the rats in the treatment group were significantly increased; with clear edges; and the arcuate cup recovered;

(14) FIG. 2A is a NMR image of Embodiment 1 shows large irregularity and uneven signals;

(15) FIG. 2B is 3 NMR image of Embodiment 1 shows uniform signals;

(16) FIG. 3A is a CT image of Embodiment 1 shows unevenly and the necrotic area in the right femoral head;

(17) FIG. 3B is a CT image of Embodiment 1 shows uniform density of the right femoral head;

(18) FIG. 4A is an X-ray image of Embodiment 1 shows the ugger and middle section of the femur 10 had skin ulceration, exudation, and necrosis, and unhealed fistulous tract;

(19) FIG. 4B is an X-ray image of Embodiment 1 shows the dead bone disappeared, the fistulous tract is healed;

(20) FIG. 5A is an X-ray image of Embodiment 2: the arrows (8) indicate the trabecular bone disagpeared in femoral head before treatment;

(21) FIG. 5B is an X-ray image of Embodiment 2: the arrows (9) indicate the trabecular bone in femoral head after treatment;

(22) FIG. 5C is an X-ray image of Embodiment 2 shows normal femoral head after treatment;

(23) FIG. 6A is an X-ray image of Embodiment 3: the arrows (10) indicate coarse surface, increased density, uneven density and epighyseal density in the femoral head;

(24) FIG. 6B is an X-ray image of Embodiment 3: the arrows (11) indicate unclear boundaries, decreased density, and uniform egighyseal density in the femoral head;

(25) FIG. 6C is an X-ray image of Embodiment 3 shows femoral head was slightly flat and had smooth surface, clear trabecular bone and uniform density after treament;

(26) FIG. 7A is an X-ray image of Embodiment 3 shows a large area of decreased density on the right side;

(27) FIG. 7B is an X-ray image of Embodiment 3 shows a normal density on the right side;

(28) FIG. 8A is a NMR image of Embodiment 4 shows the decreased signal on the right femoral head and double-line signs (view 1);

(29) FIG. 8B is a NMR image of Embodiment 4 shows the decreased signal on the right femoral head and double-line signs (view 2);

(30) FIG. 8C is a NMR image of Embodiment 4 shows the decreased signal on the right femoral head and double-line signs (view 3);

(31) FIG. 8D is a NMR image of Embodiment 4 shows the normal signal on the right femoral head and double-line signs (view 1);

(32) FIG. 8E is a NMR image of Embodiment 4 shows the normal signal on the right femoral head and double-line signs (view 2);

(33) FIG. 8F is a NMR image of Embodiment 4 shows the normal signal on the right femoral head and double-line signs (view 3);

(34) FIG. 9A is a NMR image of Embodiment 4 shows fracture and degeneration of the intervertebral cartilage plates of the lumbar spines #4 and 35;

(35) FIG. 9B is a NMR image of Embodiment 4 shows the avulsed intervertebral cartilage plate and vertebral body were repaired, and the intervertebral nerve compression and cutting disappeared after treatment.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Embodiment 1

(36) to produce a dietary supplement that promotes blood circulation and improve bone and muscle. With the experiment name of Bone-Strengthening Pill (BSP), such dietary supplement is made from the following materials: Angelica sinensis, Panax notoginseng and Carthamus tinctorius L.

(37) The raw materials are described as follows:

(38) Angelica sinensis is a perennial herb of Family Umbelliferae. Its root is one of the most common traditional Chinese medicines.

(39) Panax notoginseng is a perennial herb in the Panax ginseng genus of Family Araliaceae of Order Umbellales. Its root is used as medicine. In this study, Panax notoginseng is identified to have a role in improving microcirculation.

(40) Carthamus tinctorius L., with aliases such as Spinose Carthamus tinctorius L., is a herbal plant of Genus Carthamus tinctorius L. of Family Compositae, habitually used as traditional Chinese medicine. The study mainly utilizes Carthamus tinctorius L.'s functions to promote blood circulation and remove stasis, and to dredge blood microcirculation pathway.

(41) The ratio of Angelica sinensis:Panax notoginseng:Carthamus tinctorius L. is 280-320:55-65:12-18 by weight.

(42) The optimal ratio of Angelica sinensis:Panax notoginseng:Carthamus tinctorius L. is 300:60:15 by weight.

(43) The dietary supplement mentioned hereof may be processed and taken in a variety of ways. This embodiment only gives two examples:

(44) 1. All raw materials are powdered, screened with more 80 meshes, and then made into decoction, powder, pill, tablet or capsule. The usage is to orally take 4-10 g every time, three times a day, for adults.

(45) All raw materials are crushed, decocted in water, and made into decoction or the decoction is concentrated into decoction, powder, pill, tablet and capsule. The usage is to orally take 2-5 g every time, three times a day, for adults.

(46) Safety: The above herbs are all traditional Chinese medicinal materials applicable for long-term use, and safe and non-toxic. The dosage of this embodiment is lower than the limit specified in the relevant classic medical books, so it can be completely identified as being safe. Nevertheless, standard animal experiments and clinical trials have been conducted in this study to prove that the above compatibility of medicines is safe. The following are the experimental results of three applications:

(47) I. Experiment of Weak Population:

(48) Weakness mainly refers to the physical weakness, body discomfort, weakness after illness, postpartum weakness, weakness, shortness of breath, difficulty in walking, insomnia and forgetfulness, etc. caused by poor blood circulation,

(49) Since 2010, the multi-parameter microcirculation measuring instrument has been used to detect several physically weak persons for 16 indexes of three categories, such as loop morphology, blood flow state, and surrounding state of nail fold microcirculation. The dietary supplement was taken by those with abnormal indexes. It deemed as recovery that the indexes are improved, the symptoms disappear, and no recurrence is observed after one year of follow-up. Recovery number/Total number100%=Recovery rate

(50) The experimental situations are shown as follows:

(51) TABLE-US-00001 Average Total Recovery Recovery Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (%) (Week) Slight Abnormality 42 35 83.3 3 Moderate Abnormality 36 29 80.6 5 Severe Abnormality 32 22 68.8 8

(52) It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance.

(53) II. Experiment of Population with Bone Tissue Injury:

(54) Animal Experiment: Bone density, osteometrics, fat deposition of femoral head, capillary distribution of femoral head and related biochemical indexes were tested and studied with the castrated rat model of osteoporosis and two-legged rat model of ischemic necrosis of femoral head. The experimental results are shown in FIG. 1A-M. In FIG. 1A, the femoral head of the normal rats has smooth surface and chondrocytes arranging in a columnar manner; in FIG. 1B, the femoral head of the model rats has surface necrosis and detachment, collapse and coloboma, and loses chondrocytes; in FIG. 1C, the rats with femoral head necrosis were treated with this product (treatment group) showed that femoral head has smooth surface, is free of coloboma, and recovered chondrocytes in columnar arrangement; in FIG. 1D, the model rats show crimpiness, disorder and fracture of bone trabecula; in FIG. 1E, the model rats show the focal necrosis of intramedullary cells of femoral head; in FIG. 1F., the bone trabecula is rich and morphology is normal in the treatment group; in FIG. 1G, no necrosis was observed in myeloid cells in the treatment group; in FIG. 1H, a small number of fat particles were attached to the chondrocyte surface of the normal rat; in FIG. 1I, a large number of fat particles were contained in the chondrocytes of femoral head of the model rats; in FIG. 1J, a small number of fat particles were observed in the femoral head of the rats in the experimental group; in FIG. 1K, the capillaries of femoral head of the normal rats are abundant, with clear edges and interweaving into a network to form an arcuate cup; in FIG. 1L, the capillaries inside the femoral head of the model rats were sparse and the arcuate cup disappeared; in FIG. 1M, the capillaries of the femoral head of the rats in the treatment group were significantly increased, with clear edges, and the arcuate cup recovered.

(55) The results showed that this product can increase the minimum bone density (MBD), trabecula bone volume (TBV), mean trabecular plate thickness (MTPT) and cortical bone volume (CBV) of the model rats; can significantly increase the mineral appositional rate (MAR) and mean osteoid seam width (MOSW) of the femoral head of the model rats, decrease the fat deposition of the femoral head and enrich capillary distribution of femoral head; and bone-related biochemical tests showed the increased alkaline phosphatase (ALP) and decreased tartrate-resistant acid phosphatase (TRAP). Conclusion: This product can significantly promote bone growth, increase bone density, restore bone substance and blood supply, inhibit and reverse necrotic osteoblasts and chondrocytes, repair bone and cartilage, and is conducive to the recovery of bone and joint diseases and free of any toxic and side effects.

(56) Clinical Trial: Since 2010, this dietary supplement has been taken by many volunteers who were diagnosed by public hospitals. If the bone tissue decay was controlled or repaired, and no recurrence was observed in the two-year follow-up, it was deemed as recovery. Recovery number/Total number100%=Recovery rate. The experimental conditions are shown as follows:

(57) TABLE-US-00002 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 32 27 84.4 20 Osteonecrosis 36 29 80.6 36 Nonunion of fracture 32 28 87.5 16 Fibrous dysplasia 30 26 86.7 34 Bone cyst 30 27 90.0 30 Chondritis 34 29 85.3 26
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay.

(58) Typical Case:

(59) As shown in FIG. 2A-B: A male patient, 37 years old, had been diagnosed with bilateral femoral head necrosis for 3 years, had slight collapse and walking difficulties. He returned to normal work after 12 months of treatment. Before treatment, his MRI image showed abnormal signals of bilateral femoral head, showing large irregularity and uneven signals; abnormal signals of the right femoral head accounted for about 80%, while those of the left for about 60% (FIG. 2A). After treatment, the outline signals of femoral head were uniform, and the abnormal signal area was significantly reduced (FIG. 2B).

(60) As shown in FIG. 3A and B: A male patient, 60 years old, had been diagnosed with bilateral femoral head necrosis for 5 years and was unable to walk. He was cured after 18 months of treatment. Before treatment, his CT image showed that the density of the right femoral head increased unevenly and the necrotic area was about 60%; the left femoral head had fracture, collapse, uneven density and unclear shape, and the necrotic area was about 90% (2-1). After treatment, the density of the right femoral head was uniform and the shape was normal; the shape of the left femoral head was slightly flat, and the density basically returned to being normal (2-2).

(61) III. Experiment of Population with Muscle Tissue Decay:

(62) Muscle tissue decay refers to a variety of abnormalities of muscle tissue caused by poor blood circulation and, such as recurrent muscle sores, unhealed skin wounds, osteomyelitis, and unhealed bone tuberculosis fistula or sinus tract, degenerative arthritis and rheumatoid arthritis.

(63) Since 2010, this dietary supplement has been taken by many volunteers who were diagnosed by public hospitals. If the bone tissue decay was controlled or repaired, and no recurrence was observed in the one-year follow-up, it was deemed as recovery. Recovery number/Total number100%=Recovery rate.

(64) The experimental results are shown as follows:

(65) TABLE-US-00003 Average Total Recovery Recovery Duration of Number Number Rate Treatment Type (Person) (Person) (%) (Week) Recurrent sores 34 27 79.4 16 Unhealed wounds 36 30 83.3 15 Unhealed fistula 36 31 86.1 26 and fistulous tract Degenerative 30 24 80.0 24 arthritis Rheumatoid 36 23 63.9 36 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

(66) Typical Case: As shown in FIG. 4A and B, a male patient, 36 years old, had been diagnosed with left femoral osteomyelitis for 12 years and undergone 3 fractures and 6 surgeries successively. All the upper and middle section of the femur had skin ulceration, exudation, and necrosis, and unhealed fistulous tract. Once pus flowed, he had to lie in bed. The hospital told him to have an amputation. After 7 months of medication, his skin returned to being normal, his dead bone disappeared, his fistulous tract was healed, and he returned to work.

Embodiment 2

(67) Lumbricus, Pearl and Borneol were further included in the raw materials mentioned in Embodiment 1 to form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl and Borneol at the ratio of 280-320:55-65:12-18:80-100:2-5:2-5. Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl and Borneol at the ratio of 300:60:15:90:3:3 are preferred.

(68) Introduction to Newly Further Included Raw Materials:

(69) Lumbricus also known as Earthworm, is a representative animal in Class Oligochaeta in Phylum Annelida and one of the important traditional Chinese medicinal materials. It is a nutrient source integrating protein, vitamins, minerals and enzymes.

(70) Peal (Pernulo) is a shiny particle formed in pearl sacs of several pearly shellfishes. It is a nutrient source integrating minerals, amino acids and nutrients.

(71) Borneol, a natural crystalline compound precipitated from the resin of Kapur trees of Dipterocarpaceae plants.

(72) The processing and taking methods, safety, and experimental method of the Bone-Strengthening Pill (BSP) as a dietary supplement are the same as those of Embodiment 1:

(73) The following are the experimental results of three applications:

(74) I. The experimental situations of the weak population are as follows:

(75) TABLE-US-00004 Average Total Recovery Recovery Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (%) (Week) Slight Abnormality 46 40 87.0 3 Moderate Abnormality 36 30 83.3 5 Severe Abnormality 32 25 78.1 8
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance.
II. The experimental results of the population with bone tissue injury are shown in the following table:

(76) TABLE-US-00005 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 36 31 86.1 18 Osteonecrosis 34 29 85.3 32 Nonunion of 30 27 90.0 14 fracture Fibrous dysplasia 32 28 87.5 32 Bone cyst 36 32 88.9 30 Chondritis 30 26 86.7 25
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay, which is superior to that of Embodiment 1.

(77) Typical Case:

(78) As shown in FIG. 5A-C, a 29-year-old male patient had alcoholism. Before treatment, his femoral head had collapsed and deformation and uneven density, and the trabecular bone disappeared (FIG. 5A). There was a significant improvement after treatment (FIG. 5B). After treatment, the femoral head looked the same as before, but bone density was uniform, and the patient returned to work (FIG. 5C).
III. The experimental results of the population with muscle tissue decay are shown in the following table:

(79) TABLE-US-00006 Overall Average Total Recovery Response Duration of Number Number Rate Medication Type (Person) (Person) (ORR) (%) (Week) Recurrent sores 38 32 84.2 14 Unhealed wounds 32 29 90.6 14 Unhealed fistula 36 33 91.7 24 and fistulous tract Degenerative 32 28 87.5 22 arthritis Rheumatoid 36 24 66.7 34 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

Embodiment 3

(80) Codonopsis pilosula, Rhizoma atractylodis and Platycodonopsis grandiflorum are further included in the raw materials mentioned in Embodiment 1 to form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Codonopsis pilosula, Rhizoma atractylodis and Platycodonopsis grandiflorum at the ratio of 280-320:55-65:12-18:180-220:55-65:55-65. Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Codonopsis pilosula, Rhizoma atractylodis and Platycodonopsis grandiflorum at the ratio of 300:60:15:200:60:60 are preferred.

(81) Introduction to Newly Further Included Raw Materials:

(82) Codonopsis pilosula (Codonopsis pilosula (Franch.) Nannf. for scientific name), is a perennial herb of Genus Codonopsis of Family Campanulaceae.

(83) Rhizoma atractylodis (Atractylodes lancea (Thunb.) DC. for scientific name) is a perennial herb of Genus Atractylodes of Family Compositae.

(84) Platycodonopsis grandiflorum (Platycodon grandiflorus for scientific name), with alias such as Package Flower, Bell Flower and Mitral Flower, is a perennial herb whose root can be used as medicine.

(85) The processing and taking methods, safety, and experimental method of the dietary supplement described herein are the same as those of Embodiment 1:

(86) The following are the experimental results of three applications:

(87) I. The experimental situations of the weak population are as follows:

(88) TABLE-US-00007 Average Total Recovery Recovery Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (%) (Week) Slight Abnormality 44 40 90.9 3 Moderate Abnormality 36 31 86.1 5 Severe Abnormality 34 29 85.3 8
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance.
II. The experimental results of the population with bone tissue injury are shown in the following table:

(89) TABLE-US-00008 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 32 28 87.5 17 Osteonecrosis 32 27 84.4 30 Nonunion of 32 29 90.6 13 fracture Fibrous dysplasia 34 29 85.3 30 Bone cyst 32 28 87.5 29 Chondritis 33 29 87.9 25
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay.

(90) Typical Case:

(91) As shown in FIG. 6A-C, a female patient, 9 years old, has been sick for 2 years and recovered after 16 months of medication. Before treatment, her femoral head had coarse surface, increased density, uneven density and epiphyseal density (FIG. 6A). After 7 months of treatment, her femoral head had unclear boundaries, decreased density, and uniform epiphyseal density (FIG. 6B). After treatment, her femoral head was slightly flat and had smooth surface, clear trabecular bone and uniform density (FIG. 6C).

(92) As shown in FIG. 7A and B, a patient, 45 years old, had a large area of decreased density on the right side according to the X-ray image, and recovered after taking the medicine.

(93) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(94) TABLE-US-00009 Overall Average Total Recovery Response Duration of Number Number Rate Medication Type (Person) (Person) (ORR) (%) (Week) Recurrent sores 32 28 87.5 14 Unhealed wounds 36 34 94.4 14 Unhealed fistula 32 30 93.8 22 and fistulous tract Degenerative 34 29 85.3 22 arthritis Rheumatoid 36 25 69.4 32 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay, which is superior to that of Embodiment 1.

Embodiment 4

(95) Lumbricus, Pearl, Borneol, Codonopsis pilosula, Rhizoma atractylodis and Platycodonopsis grandiflorum are further included in the raw materials mentioned in Embodiment 1 to form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl, Borneol, Codonopsis pilosula, Rhizoma atractylodis and Platycodonopsis grandiflorum at the ratio of 280-320:55-65:12-18:80-100:2-5:2-5:180-220:55-65:55-65.

(96) The optimal ratio of Angelica sinensis:Panax notoginseng:Carthamus tinctorius L.:Lumbricus:Pearl:Borneol: Codonopsis pilosula:Rhizoma atractylodis:Platycodonopsis grandiflorum is 300:60:15:90:3:3:200:60:60 by weight.

(97) The processing method of the dietary supplement mentioned herein is to powder all raw materials, screen the powder with more 80 meshes, and then made into decoction, powder, pill, tablet or capsule.

(98) The usage of the dietary supplement is to orally take 5-12 g every time, three times a day, for adults.

(99) The processing method of the dietary supplement mentioned herein is to crush all raw materials, decoct them in water, and make into decoction or concentrate the decoction into decoction, powder, pill, tablet or capsule.

(100) The usage of the dietary supplement is to orally take 3-6 g every time, three times a day, for adults.

(101) The experimental method is the same as that Embodiment 1. The following are the experimental results of three applications:

(102) I. The experimental situations of the weak population are as follows:

(103) TABLE-US-00010 Overall Average Total Recovery Response Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (ORR) (%) (Week) Slight Abnormality 43 40 93.0 3 Moderate Abnormality 33 29 87.9 5 Severe Abnormality 36 31 86.1 8
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance.

(104) II. The experimental results of the population with bone tissue injury are shown in the following table:

(105) TABLE-US-00011 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 34 30 88.2 16 Osteonecrosis 36 32 88.9 30 Nonunion of 32 30 93.8 12 fracture Fibrous dysplasia 36 32 88.9 28 Bone cyst 36 33 91.7 27 Chondritis 30 27 90.0 20
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay.

(106) Typical Case:

(107) As shown in FIG. 8A-F, a patient, 59 years old, had the decreased signal on the right femoral head and double-line signs (FIG. 8A-C) before treatment. The signal returned to normal after treatment (FIG. 8D-F).

(108) As shown in FIG. 9A and B, a patient, 38 years old, had lumbar sprain, vertebral cartilage avulsion, intervertebral disc herniation, and low back pain with pain in both lower limbs, and was unable to get out of bed or move. He was cured after three months of treatment. Before treatment, the MRI image showed fracture and degeneration of the intervertebral cartilage plates of the lumbar spines #4 and 35, vertebral body avulsion at the ligamentous attachment, intervertebral disc protrusion to the spinal canal, and obvious compression of the nerves in the spinal canal (A). After treatment, the avulsed intervertebral cartilage plate and vertebral body were repaired, and the intervertebral nerve compression and cutting disappeared (B).

(109) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(110) TABLE-US-00012 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Recurrent sores 36 33 91.7 13 Unhealed wounds 38 36 94.7 12 Unhealed fistula 32 30 93.8 20 and fistulous tract Degenerative 30 27 90.0 20 arthritis Rheumatoid 36 26 72.2 30 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

Embodiment 5

(111) Paeonia lactiflora Pall, Ligusticum wallichii, Polygala tenuifolia and Panax quinquefolius are further included in the raw materials Angelica sinensis, Panax notoginseng and Carthamus tinctorius L. to form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Paeonia lactiflora Pall, Ligusticum wallichii, Polygala tenuifolia and Panax quinquefolius at the ratio of 280-320:55-65:12-18:80-100:25-35:25-35:2-5.

(112) Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Paeonia lactiflora Pall, Ligusticum wallichii, Polygala tenuifolia and Panax quinquefolius at the ratio of 300:60:15:90:30:30:3 are preferred.

(113) Introduction to Newly Further Included Raw Materials:

(114) Paeonia lactiflora Pall is dry root of Paeonia tactilora Pall., a Ranunculaceae plant.

(115) Ligusticum wallichii (Scientific name: Ligusticum chuanxiong Hort) is a herbal plant for traditional Chinese medicine.

(116) Polygala tenuifolia (Scientific name: Polygala tenuifolia Willd), also known as Fine Grass and Line Tea, is a perennial herb. Traditional Chinese medicine believes that Polygala tenuifolia has the functions of tranquilizing mind, promoting intelligence, and relieving sputum and swelling. This application is based on the close relationship between human microcirculation and e regulation of the nervous system, so Polygala tenuifolia is used.

(117) Panax quinquefolius (Scientific name: Panax quinquefolius) is a perennial plant of Genus Panax of Family Araliaceae.

(118) The processing and taking methods, safety and experimental method of the dietary supplement mentioned herein are the same as those of Embodiment 4.

(119) The following are the experimental results of three applications:

(120) I. The experimental situations of the weak population are shown in the following table:

(121) TABLE-US-00013 Average Total Recovery Overall Duration of Microcirculation Number Number Response Rate Medication Index (Person) (Person) (ORR) (%) (Week) Slight Abnormality 45 42 93.3 2 Moderate 34 30 88.2 4 Abnormality Severe Abnormality 36 31 86.1 7
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance, and the time to response is significantly shortened.

(122) II. The experimental results of the population with bone tissue injury are shown in the following table:

(123) TABLE-US-00014 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 36 31 86.1 14 Osteonecrosis 32 28 87.5 28 Nonunion of 36 34 94.4 10 fracture Fibrous dysplasia 32 28 87.5 26 Bone cyst 34 31 91.2 26 Chondritis 36 32 88.9 18
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay, which is superior to that of Embodiment 1.

(124) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(125) TABLE-US-00015 Average Total Recovery Duration of Number Number Recovery Medication Type (Person) (Person) (%) (Week) Recurrent sores 36 31 86.1 13 Unhealed wounds 36 33 91.7 6 Unhealed fistula 36 34 94.4 18 and fistulous tract Degenerative 32 29 90.6 18 arthritis Rheumatoid 36 28 77.8 28 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

Embodiment 6

(126) Lumbricus, Pearl, Borneol, Paeonia lactiflora Pall, Ligusticum wallichii, Polygala tenuifolia and Panax quinquefolius are further included in the raw materials form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl, Borneol, Paeonia lactiflora Pall, Ligusticum wallichii, Polygala tenuifolia and Panax quinquefolius at the ratio of 280-320:55-65:12-18:80-100:2-5:2-5:80-100:25-35:25-35:2-5. Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl, Borneol, Paeonia lactiflora Pall, Ligusticum wallichii, Polygala tenuifolia and Panax quinquefolius at the ratio of 300:60:15:90:3:3:90:30:30:3 are preferred.

(127) The processing and taking methods, safety and experimental method of the dietary supplement described herein are the same as those of Embodiment 4:

(128) The following are the experimental results of three applications:

(129) I. The experimental situations of the weak population are as follows:

(130) TABLE-US-00016 Overall Average Total Recovery Response Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (ORR) (%) (Week) Slight Abnormality 44 42 95.5 2 Moderate Abnormality 36 33 91.7 4 Severe Abnormality 32 30 93.8 7
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance, and the time to response is significantly shortened.

(131) II. The experimental results of the population with bone tissue injury are shown in the following table:

(132) TABLE-US-00017 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 36 32 88.9 12 Osteonecrosis 36 31 86.1 26 Nonunion of 32 31 96.6 9 fracture Fibrous dysplasia 32 30 93.8 24 Bone cyst 36 33 91.7 24 Chondritis 32 29 90.6 16
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay, which is superior to that of Embodiment 1.

(133) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(134) TABLE-US-00018 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Recurrent sores 36 34 94.4 12 Unhealed wounds 36 35 97.2 3 Unhealed fistula 32 31 96.9 18 and fistulous tract Degenerative 32 29 90.6 16 arthritis Rheumatoid 36 29 80.6 26 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

Embodiment 7

(135) Atractylodes macrocephala, Semen coicis, Dioscorea opposita Thunb and Pseudostellaria heterophylla are further included in the raw materials Angelica sinensis, Panax notoginseng, and Carthamus tinctorius L., to form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Atractylodes macrocephala, Semen coicis, Dioscorea opposita Thunb and Pseudostellaria heterophylla at the ratio of 280-320:55-65:12-18:80-100:28-32:28-32:2-5.

(136) Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Atractylodes macrocephala, Semen coicis, Dioscorea opposita Thunb and 3 Pseudostellaria heterophylla at the ratio of 300:60:15:90:30:30:3 are preferred.

(137) Introduction to Newly Further Included Raw Materials:

(138) Atractylodes macrocephala, with aliases such as Raft Thistle, Winter Atractylodes macrocephala, Yang beam, Poplar Raft, is a perennial herb in Genus Atractylodes in Family Composite. Its rhizome is used as medicine.

(139) Semen coicis (Coix chinensisTod.), also known as Seed of Job's Tears seed and Six Millet Seed, is seed of Coix, a plant of Family Grass.

(140) Dioscorea opposita Thunb, also known as Common Yam Rhizome, Rhizome of Common Yam, Dioscoreae rhizome, Yam, Roachster, and White Yam, is dry rhizome of Dioscorea opposita Thunb, a plant of Family Dioscoreaceae.

(141) Pseudostellaria heterophylla, Pseudostellaria heterophylla (Miq) Pax for scientific name, belongs to Genus Pseudostellaria in Family Caryophyllaceae (Pseudostellaria heterophylla (Miq) Pax ex Pax et Hoffm). Its root is used as medicine.

(142) The processing and taking methods, safety and experimental method of the dietary supplement mentioned herein are the same as those of Embodiment 4.

(143) The following are the experimental results of three applications:

(144) I. The experimental situations of the weak population are as follows:

(145) TABLE-US-00019 Overall Average Total Recovery Response Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (ORR) (%) (Week) Slight Abnormality 50 48 96.0 2 Moderate Abnormality 36 34 94.4 4 Severe Abnormality 32 28 87.5 7
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance and the time to response is significantly shortened.

(146) II. The experimental results of the population with bone tissue injury are shown in the following table:

(147) TABLE-US-00020 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 36 32 88.9 14 Osteonecrosis 32 28 87.5 28 Nonunion of 42 40 95.2 10 fracture Fibrous dysplasia 36 32 88.9 26 Bone cyst 34 31 91.2 26 Chondritis 32 29 90.6 18
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay, which is superior to that of the previous embodiments.

(148) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(149) TABLE-US-00021 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Recurrent sores 36 32 88.9 13 Unhealed wounds 32 30 93.8 6 Unhealed fistula 32 31 96.9 18 and fistulous tract Degenerative 36 33 91.7 18 arthritis Rheumatoid 36 29 80.6 28 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

Embodiment 8

(150) Lumbricus, Pearl, Borneol, Atractylodes macrocephala, Semen coicis, Dioscorea opposita Thunb and Pseudostellaria heterophylla are further included to the raw materials, form a form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl, Borneol, Atractylodes macrocephala, Semen coicis, Dioscorea opposita Thunb and Pseudostellaria heterophylla at the ratio of 180-220:55-65:12-18:80-100:2-5:2-5:80-100:28-32:28-32:2-5.

(151) Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl, Borneol, Atractylodes macrocephala, Semen coicis, Dioscorea opposita Thunb and Pseudostellaria heterophylla at the ratio of 200:60:15:90:3:3:90:30:30:3 are preferred.

(152) The processing and taking methods, safety and experimental method of the dietary supplement mentioned herein are the same as those of Embodiment 4. The following are the experimental results of three applications:

(153) I. The experimental situations of the weak population are as follows:

(154) TABLE-US-00022 Overall Average Total Recovery Response Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (ORR) (%) (Week) Slight Abnormality 56 54 96.4 2 Moderate Abnormality 42 40 95.2 4 Severe Abnormality 32 29 90.6 7
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance, and the time to response is significantly shortened.

(155) II. The experimental results of the population with bone tissue injury are shown in the following table:

(156) TABLE-US-00023 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 36 33 91.6 14 Osteonecrosis 32 29 90.6 28 Nonunion of 43 42 97.7 10 fracture Fibrous dysplasia 36 33 91.6 26 Bone cyst 36 33 91.6 26 Chondritis 38 35 92.1 18
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay, which is superior to that of the previous embodiments.

(157) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(158) TABLE-US-00024 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Recurrent sores 38 35 92.1 13 Unhealed wounds 32 31 96.9 6 Unhealed fistula 36 35 97.2 18 and fistulous tract Degenerative 36 33 91.7 18 arthritis Rheumatoid 36 30 83.3 28 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

Embodiment 9

(159) Astragalus membranaceus, Psoralen, Polygala tenuifolia and Radix glycyrrhizae are further included to the raw materials Angelica sinensis, Panax notoginseng and Carthamus tinctorius L., to form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Astragalus membranaceus, Psoralen, Polygala tenuifolia and Radix glycyrrhizae at the ratio of 180-220:55-65:12-18:80-100:28-32:28-32:2-5.

(160) Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Astragalus membranaceus, Psoralen, Polygala tenuifolia and Radix glycyrrhizae at the ratio of 200:60:15:90:30:30:3 are preferred

(161) Introduction to Newly Further Included Raw Materials:

(162) Astragalus membranaceus (Stragalus membranaceus (Fisch.) Bunge.), also known as Radix astragali, is a perennial herb of Genus Astragalus of Order Rosaceae of Family Leguminosae.

(163) Psoralea (Scientific name: Psoralea corylifolia Linn.), also known as Fructus psoraleae, is an annual erect herb of Order Rosaceae of Family Leguminosae. Its fruit is used as medicine.

(164) Radix glycyrrhizae (Scientific name: Glycyrrhiza uralensis Fisch), also known as Sweet Grass and Sweet Root, is a perennial herb of Order Glycyrrhiza of Family Leguminosae.

(165) The processing and taking methods, safety and experimental method of the dietary supplement mentioned herein are the same as those of Embodiment 4.

(166) The following are the experimental results of three applications:

(167) I. The experimental situations of the weak population are as follows:

(168) TABLE-US-00025 Overall Average Total Recovery Response Duration of Number Number Rate Medication Microcirculation Index (Person) (Person) (ORR) (%) (Week) Slight Abnormality 65 61 93.8 2 Moderate Abnormality 54 49 90.7 4 Severe Abnormality 36 32 88.9 7
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance.

(169) II. The experimental results of the population with bone tissue injury are shown in the following table:

(170) TABLE-US-00026 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 38 34 89.5 14 Osteonecrosis 36 32 88.9 28 Nonunion of 39 38 97.4 10 fracture Fibrous dysplasia 36 33 91.7 26 Bone cyst 38 35 92.1 26 Chondritis 36 33 91.7 18
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay, which is superior to that of Embodiment 1.

(171) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(172) TABLE-US-00027 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Recurrent sores 46 41 89.1 13 Unhealed wounds 42 39 92.9 6 Unhealed fistula 44 42 95.5 18 and fistulous tract Degenerative 36 33 91.7 18 arthritis Rheumatoid 46 41 89.1 28 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

Embodiment 10

(173) Lumbricus, Pearl, Borneol, Astragalus membranaceus, Psoralen, Polygala tenuifolia and Radix glycyrrhizae are further included in the raw materials Angelica sinensis, Panax notoginseng and Carthamus tinctorius L., to a form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl, Borneol, Astragalus membranaceus, Psoralen, Polygala tenuifolia and Radix glycyrrhizae at the ratio of 180-220:55-65:12-18:80-100:2-5:2-5:80-100:28-32:28-32:2-5.

(174) Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl, Borneol, Astragalus membranaceus, Psoralen, Polygala tenuifolia and Radix glycyrrhizae at the ratio of 200:60:15:90:3:3:90:30:30:3 are preferred.

(175) The processing method of the dietary supplement mentioned herein is to powder all raw materials, screen the powder with more 80 meshes, and then made into decoction, powder, pill, tablet or capsule.

(176) The usage of the dietary supplement is to orally take 5-12 g every time, three times a day, for adults.

(177) The processing and taking methods, safety and experimental method of the dietary supplement mentioned herein are the same as those of Embodiment 4.

(178) The following are the experimental results of three applications:

(179) I. The experimental situations of the weak population are as follows:

(180) TABLE-US-00028 Overall Average Total Recovery Response Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (ORR) (%) (Week) Slight Abnormality 63 60 95.2 2 Moderate Abnormality 56 52 92.9 4 Severe Abnormality 38 34 89.5 7
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance.

(181) II. The experimental results of the population with bone tissue injury are shown in the following table:

(182) TABLE-US-00029 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 41 38 92.7 14 Osteonecrosis 36 33 91.7 28 Nonunion of 52 51 98.1 10 fracture Fibrous dysplasia 36 33 91.7 26 Bone cyst 40 37 92.5 26 Chondritis 38 35 92.1 18
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay, which is superior to that of Embodiment 1.

(183) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(184) TABLE-US-00030 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Recurrent sores 49 45 91.8 13 Unhealed wounds 42 40 95.2 6 Unhealed fistula 48 46 95.8 18 and fistulous tract Degenerative 36 34 94.4 18 arthritis Rheumatoid 48 44 91.7 28 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

Embodiment 11

(185) Achyranthes bidentata, Sealwort, Paeonia lactiflora Pall and Eurycoma longifolia are further included in the raw materials Angelica sinensis, Panax notoginseng and Carthamus tinctorius L., to form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Achyranthes bidentata, Sealwort, Paeonia lactiflora Pall and Eurycoma longifolia at the ratio of 180-220:55-65:12-18:28-32:28-32: 80-100:2-5. Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Achyranthes bidentata, Sealwort, Paeonia lactiflora Pall and Eurycoma longifolia at the ratio of 200:60:15:30:30:90:3 are preferred.

(186) Introduction to Newly Further Included Raw Materials:

(187) Achyranthes bidentata (Latin name: Achyranthes bidentata Blume.), also known as Hyssop, is a perennial herb of Genus Hyssop of Family Amaranthaceae.

(188) Achyranthes bidentata (Scientific name: Polygonatum sibiricum), also known as Chicken Head Yellow Essence, Yellow Chicken Vegetable, and Pen Tube Vegetable.

(189) Eurycoma longifolia is a wild shrub in tropical rain forests around the equator in Southeast Asia. It belongs to Genus Euryalium of Family Simarubaceae of Sapindales Order. Its root has various effects.

(190) The processing and taking methods, safety and experimental method of the dietary supplement mentioned herein are the same as those of Embodiment 4. The following are the experimental results of three applications:

(191) I. The experimental situations of the weak population are as follows:

(192) TABLE-US-00031 Overall Average Total Recovery Response Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (ORR) (%) (Week) Slight Abnormality 50 47 94.0 2 Moderate Abnormality 44 40 90.9 4 Severe Abnormality 38 33 86.8 7
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance.

(193) II. The experimental results of the population with bone tissue injury are shown in the following table:

(194) TABLE-US-00032 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 44 39 88.6 14 Osteonecrosis 36 32 88.9 28 Nonunion of 50 48 96.0 10 fracture Fibrous dysplasia 36 32 88.9 26 Bone cyst 39 36 92.3 26 Chondritis 38 35 92.1 18
It indicates that this product has a good repair and improvement effect on various types of bone tissue decay.

(195) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(196) TABLE-US-00033 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Recurrent sores 46 41 89.1 13 Unhealed wounds 44 42 95.5 6 Unhealed fistula 36 35 97.2 18 and fistulous tract Degenerative 42 40 95.2 18 arthritis Rheumatoid 36 30 83.3 28 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

Embodiment 12

(197) Lumbricus, Pearl, Borneol, Achyranthes bidentata, Sealwort, Paeonia lactiflora Pall and Eurycoma longifolia are further included in the raw materials Angelica sinensis, Panax notoginseng and Carthamus tinctorius L., to form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl, Borneol, Achyranthes bidentata, Sealwort, Paeonia lactiflora Pall and Eurycoma longifolia at the ratio of 180-220:55-65:12-18:80-100:2-5:2-5:28-32:28-32: 80-100:2-5.

(198) Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl, Borneol, Achyranthes bidentata, Sealwort, Paeonia lactiflora Pall and Eurycoma longifolia at the ratio of 200:60:15:90:3:3:30:30:90:3 are preferred.

(199) The processing and taking methods, safety and experimental method of the dietary supplement mentioned herein are the same as those of Embodiment 4.

(200) The following are the experimental results of three applications:

(201) I. The experimental situations of the weak population are as follows:

(202) TABLE-US-00034 Overall Average Total Recovery Response Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (ORR) (%) (Week) Slight Abnormality 56 54 96.4 2 Moderate Abnormality 54 51 94.4 4 Severe Abnormality 42 38 90.5 7
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance.

(203) II. The experimental results of the population with bone tissue injury are shown in the following table:

(204) TABLE-US-00035 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 48 44 91.7 14 Osteonecrosis 38 36 94.7 28 Nonunion of 62 61 98.4 10 fracture Fibrous dysplasia 36 33 91.6 26 Bone cyst 42 40 95.2 26 Chondritis 38 36 94.7 18
It indicates that this product has a good repair and improvement effect on various types of bone tissue decay.

(205) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(206) TABLE-US-00036 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Recurrent sores 46 43 93.4 13 Unhealed wounds 48 47 97.9 6 Unhealed fistula 46 45 97.8 18 and fistulous tract Degenerative 46 44 95.7 18 arthritis Rheumatoid 38 33 86.8 28 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

Embodiment 13

(207) Ligusticum wallichii, Rehmannia glutinosa, Eucommia ulmoides and Rhodiola rosea are further included in the raw materials Angelica sinensis, Panax notoginseng and Carthamus tinctorius L., to form a reinforced formula, with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Ligusticum wallichii, Rehmannia glutinosa, Eucommia ulmoides and Rhodiola rosea at the ratio of 180-220:55-65:12-18:80-100:28-32:28-32:2-5.

(208) Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Ligusticum wallichii, Rehmannia glutinosa, Eucommia ulmoides and Rhodiola rosea at the ratio of 200:60:15:90:30:30:3 are preferred.

(209) Introduction to Newly Further Included Raw Materials:

(210) Rehmannia glutinosa is the earthnut of Rehmannia Glutinosa (Latin name:Chinese Foxglove), also known as Prepared Rehmannia or Foxglove.

(211) Eucommia ulmoides (Scientific name: Eucommia ulmoides Oliver), also known as Bakelite, is a plant of Family Eucommiaceae. Its dry bark is used as medicine.

(212) Rhodiola rosea (Scientific name: Rhodiola rosea L.), with the alias of Rose Rhodiola rosea and Saul Mapur (Tibetan name), is a perennial herb of Family Crassulaceae of Order Rrosaceae.

(213) The processing and taking methods, safety and experimental method of the dietary supplement mentioned herein are the same as those of Embodiment 4.

(214) The following are the experimental results of three applications:

(215) I. The experimental situations of the weak population are as follows:

(216) TABLE-US-00037 Overall Average Total Recovery Response Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (ORR) (%) (Week) Slight Abnormality 55 53 96.4 3 Moderate Abnormality 44 41 93.2 5 Severe Abnormality 39 34 87.2 8
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance.

(217) II. The experimental results of the population with bone tissue injury are shown in the following table:

(218) TABLE-US-00038 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 45 41 91.1 14 Osteonecrosis 40 37 92.5 28 Nonunion of 46 45 97.8 10 fracture Fibrous dysplasia 42 39 92.9 26 Bone cyst 38 36 94.7 26 Chondritis 36 34 94.4 18
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay, which is superior to that of Embodiment 1.

(219) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(220) TABLE-US-00039 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Recurrent sores 56 52 92.9 13 Unhealed wounds 54 51 94.4 6 Unhealed fistula 36 35 97.2 18 and fistulous tract Degenerative 42 40 95.2 18 arthritis Rheumatoid 46 40 87.0 28 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.

Embodiment 14

(221) Lumbricus, Pearl, Borneol, Ligusticum wallichii, Rehmannia glutinosa, Eucommia ulmoides and Rhodiola rosea are further included in the raw materials, to form a reinforced formula with Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl, Borneol, Ligusticum wallichii, Rehmannia glutinosa, Eucommia ulmoides and Rhodiola rosea at the ratio of 180-220:55-65:12-18:80-100:2-5:2-5:80-100:28-32:28-32:2-5.

(222) Angelica sinensis, Panax notoginseng, Carthamus tinctorius L., Lumbricus, Pearl, Borneol, Ligusticum wallichii, Rehmannia glutinosa, Eucommia ulmoides and Rhodiola rosea at the ratio of 200:60:15:90:3:3:90:30:30:3 are preferred.

(223) The processing and taking methods, safety and experimental method of the dietary supplement mentioned herein are the same as those of Embodiment 4.

(224) The following are the experimental results of the three applications:

(225) I. The experimental situations of the weak population are as follows:

(226) TABLE-US-00040 Overall Average Total Recovery Response Duration of Microcirculation Number Number Rate Medication Index (Person) (Person) (ORR) (%) (Week) Slight Abnormality 58 57 98.3 3 Moderate Abnormality 54 52 96.3 5 Severe Abnormality 38 34 89.5 8
It indicates that this product has a good repair and improvement effect on a variety of microcirculation disturbance.

(227) II. The experimental results of the population with bone tissue injury are shown in the following table:

(228) TABLE-US-00041 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Osteoporosis 55 52 94.5 14 Osteonecrosis 60 57 95.0 28 Nonunion of 66 65 98.5 10 fracture Fibrous dysplasia 52 49 94.2 26 Bone cyst 49 47 95.9 26 Chondritis 46 44 95.6 18
It indicates that this product has a good repair and improvement effect on multiple types of bone tissue decay, which is superior to that of Embodiment 1.

(229) III. The experimental results of the population with muscle tissue decay are shown in the following table:

(230) TABLE-US-00042 Average Total Recovery Recovery Duration of Number Number Rate Medication Type (Person) (Person) (%) (Week) Recurrent sores 55 52 94.5 13 Unhealed wounds 58 56 96.6 6 Unhealed fistula 62 61 98.4 18 and fistulous tract Degenerative 52 50 96.2 18 arthritis Rheumatoid 48 43 89.6 28 arthritis
It indicates that this product has a good repair and improvement effect on various types of muscle tissue decay.